UNSPSC 51413206: Cinepazide maleate

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y35B3VA60V. European Medicines Agency schedules Cinepazide maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01311MIG. Cinepazide maleate generally arises in the molecular formula C22H31N3O5.C4H4O4. The term 'cinepazide maleate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule cinepazide maleate under HS 29335995 and SITC 51576.

As of Q4 2014, CINEPAZIDE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CC(CC(C1OC)OC)/C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51413206 Cinepazide maleate is a Commodity code covering a specific pharmaceutical active ingredient used in injectable formulations for emergency and critical-care settings. State and local governments procure this medication and related advanced life support drugs through municipal fire departments, emergency medical services, and state health agencies. The work involves supplying pharmaceuticals that meet strict expiration, storage, and regulatory compliance requirements — vendors must maintain cGMP certification, provide Safety Data Sheets compliant with OSHA Hazard Communication Standards, meet FDA requirements, and often warrant products against defects for a minimum of one year. Issuing bodies include city purchasing departments procuring on behalf of fire rescue services, state health and human services commissions, and multistate cooperative purchasing consortiums serving participating state and local governments. Recent solicitations show municipal fire departments and state pharmacy benefit programs are the primary buyers under this code.

Activity is concentrated in Florida and Texas, with multistate cooperative purchasing activity anchored in Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications in April 2026, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for Tampa Fire Rescue, with a firm response deadline of April 8, 2026 and estimated contract value of $40,000.00; the bid designated a 5 percent Small Local Business Enterprise sheltered market discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling future procurement activity in state pharmacy benefit administration. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with a March 26, 2026 response date and July 1, 2026 contract effectiveness; awards are weighted 75 percent on price competitiveness and require vendors to maintain relationships with three authorized wholesalers and comply with Drug Supply Chain Security Act requirements.